Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Frédéric Delouvroy"'
Autor:
Kristof Van Emelen, Kenneth Simmen, Frederik Pauwels, Mourad Daoubi Khamlichi, Pierre Jean-Marie Bernard Raboisson, David McGowan, Alex De Groot, Frédéric Delouvroy
Publikováno v:
Molecular diversity. 21(2)
Direct acting antiviral agents to cure hepatitis C virus (HCV) infection has emerged as the gold standard therapy. Along with protease inhibitors, nucleoside polymerase inhibitors and non-nucleoside polymerase inhibitors, the inhibition of NS5a has p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cc87adf29694b08a344db704f8de84e
https://pubmed.ncbi.nlm.nih.gov/28293834
https://pubmed.ncbi.nlm.nih.gov/28293834
Autor:
David McGowan, Origène Nyanguile, Maxwell D. Cummings, Sandrine Vendeville, Koen Vandyck, Walter Van den Broeck, Carlo W. Boutton, Hendrik De Bondt, Ludo Quirynen, Katie Amssoms, Jean-François Bonfanti, Stefaan Last, Klara Rombauts, Abdellah Tahri, Lili Hu, Frédéric Delouvroy, Katrien Vermeiren, Geneviève Vandercruyssen, Liesbet Van der Helm, Erna Cleiren, Wendy Mostmans, Pedro Lory, Geert Pille, Kristof Van Emelen, Gregory Fanning, Frederik Pauwels, Tse-I Lin, Kenneth Simmen, Pierre Raboisson
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:2492-2496
Optimization through parallel synthesis of a novel series of hepatitis C virus (HCV) NS5B polymerase inhibitors led to the identification of ( R )-11-(4-benzyloxy-2-fluorophenyl)-6-hydroxy-3,3-dimethyl-10-(6-methylpyridine-2-carbonyl)-2,3,4,5,10,11-h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8521efff0fc4c0c065284cf8f74ff171
https://doi.org/10.1016/j.bmcl.2009.03.035
https://doi.org/10.1016/j.bmcl.2009.03.035
Autor:
Frédéric Delouvroy, Laetitia Malphettes, An-Vy Tran, Gaetan Siriez, Nadine Kochanowski, Larissa Mukankurayija
Publikováno v:
BMC Proceedings
Background Enhancing throughput of bioprocess development has become increasingly important to rapidly screen and optimize cell culture process parameters. With increasing timeline pressures to get therapeutic candidates into the clinic, resource int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90b5b0928e8e2ab9cd5a785c4adf788a
https://doi.org/10.1186/1753-6561-9-s9-p78
https://doi.org/10.1186/1753-6561-9-s9-p78
Autor:
Matthew Hinchliffe, Laetitia Malphettes, Guillaume Le Reverend, Marie-Françoise Clincke, Jimmy Stofferis, Frédéric Delouvroy
Publikováno v:
BMC Proceedings
Materials and methods AmbrTM 48 and 80L stirred tank bioreactor were run for 14 days in a fed-batch mode in a chemically defined medium. A CHO cell line expressing a recombinant monoclonal antibody (MAb) was used. Feed was added daily from day 3 onwa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a028027a2bb4bb4015206dcc53cc289
https://doi.org/10.1186/1753-6561-9-s9-p34
https://doi.org/10.1186/1753-6561-9-s9-p34
Autor:
Nadine Kochanowski, Boris Fessler, Frédéric Delouvroy, Mareike Harmsen, Laetitia Malphettes, Grégory Mathy, Guillaume Le Reverend
Publikováno v:
BMC Proceedings
Bio-pharmaceutical industries face an increasing demand to accelerate process development and reduce costs. This challenge requires high throughput tools to replace the traditional combination of shake flasks and small-scale stirred tank bioreactors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ae47ead49e1f1e0bade3d0289731851
https://doi.org/10.1186/1753-6561-7-s6-p73
https://doi.org/10.1186/1753-6561-7-s6-p73